Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA

Rich Duprey

Mon, September 14, 2026 at 5:07 PM GMT+3 7 min read

Quick Read

Realty Income (O) declared its 674th consecutive monthly dividend at a 5.19% yield; Procter & Gamble (PG) has raised its payout for 70 straight years.
Roth IRAs eliminate federal tax on qualified REIT distributions, which are otherwise taxed as ordinary income, maximizing the compounding power of high yields.
AbbVie's Skyrizi and Rinvoq each surged roughly 24% in Q2 2026, driving 10.2% revenue growth as Humira biosimilar erosion continues at 36%.
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Johnson & Johnson didn't make the cut. Enter your email to see the names that beat JNJ. The report is free. Enter your email and see if any of your stocks made the cut.

A Roth IRA turns every dividend into a tax shield: qualified distributions in retirement escape federal income tax entirely, and reinvested payouts compound without a drag from Uncle Sam. That advantage is especially potent for REIT distributions, which are typically taxed as ordinary income in a taxable account. The five blue chips below combine long payment histories with the kind of cash-flow durability that makes them staples of tax-advantaged accounts. One data point that frames the group: Realty Income (NYSE:O) just declared its 136th monthly dividend increase on September 8, 2026.

bangoland / Shutterstock.com

Realty Income: The Monthly Paycheck REIT

Realty Income currently yields 5.19%, the only true high-yield name in this group. The latest monthly dividend of $0.2715 per share is payable October 15, 2026, and the company just announced its 674th consecutive monthly dividend.

Dividend safety looks sound for a net-lease REIT of this scale. Q2 2026 AFFO per share was $1.09, up 3.8% year over year, and management raised full-year AFFO guidance to $4.44 to $4.45, which more than covers the annualized $3.252 payout. Portfolio occupancy is 98.8%, rent recapture on renewals is 102.7%, and Fitch reaffirmed its "A" long-term issuer rating.

Free Report, Just Released

Why Didn't JNJ Make The Top 10 List?

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

And JNJ didn't make the cut!

The report is free, and you can see why we think each stock is a top investment today.

Enter Your Email and See the Ten →

The bull case is simple: monthly cash flow from a diversified base of freestanding retail, industrial, and increasingly data center properties, with a new $6 billion hyperscale data center joint venture pushing the growth story into a hotter asset class. The caveat is leverage. Net Debt/Adjusted EBITDAre ticked up to 5.4x from 5.2x, and 65.7% of annualized base rent comes from non-investment-grade tenants. Because REIT payouts are typically ordinary-income dividends, sheltering them in a Roth is where the tax math bites hardest.

Johnson & Johnson: Dividend King With a Pharma Engine

Johnson & Johnson (NYSE:JNJ) yields 1.97% on a quarterly dividend of $1.34 per share. Earlier this year the board raised the payout 3.1% from $1.30 to $1.34, marking 64 consecutive years of dividend increases, deep Dividend King territory.

Coverage is generous. J&J generated $19.7 billion of free cash flow in fiscal 2025 against a payout that runs well inside operating cash generation, and the company carries a AAA-tier balance sheet profile. Q1 2026 revenue reached $24.06 billion, up 9.9% year over year, with adjusted EPS of $2.70 topping consensus.

The bull case is a broadening innovative-medicine engine: DARZALEX grew 22.5% to $3.96 billion, TREMFYA jumped 68.3%, and CARVYKTI added 62.1%. Management lifted 2026 revenue guidance to $100.3 to $101.3 billion. The risk is well telegraphed: STELARA biosimilar erosion of roughly 1,040 basis points to the Innovative Medicine segment, plus ongoing litigation charges.

Coca-Cola: Global Cash Machine Still Compounding

Coca-Cola (NYSE:KO) yields 2.37% on a quarterly payout of $0.53 per share, up from $0.51 in 2025. It is one of the market's most reliable dividend growers, with a Dividend King status backed by decades of annual raises in the dividend record.

Safety is anchored by profitability that few consumer companies match: ROE of 45.97%, gross margin of 61.6%, and net margin of 27.3%. Full-year 2026 free cash flow guidance was lifted to roughly $12.4 billion, and net debt/EBITDA sits at a manageable 2.49x with interest coverage of 8.32x. Cash on the balance sheet climbed to $12.9 billion, up 34.6% year over year.

The bull case: pricing power plus volume growth. Q2 delivered 5% global unit case volume growth, with Coca-Cola Zero Sugar up 16% and operating margin expanding to 34.9%. Management raised 2026 comparable EPS growth guidance to 9% to 10%. The caveat is valuation: price-to-free-cash-flow is elevated at 71.7, and an ongoing IRS tax dispute remains an overhang.

AbbVie: Post-Humira Growth Story Reasserts Itself

AbbVie (NYSE:ABBV) yields 2.68% on a quarterly dividend of $1.73 per share, up from $1.64 in 2025. The company declared its latest quarterly dividend on September 10, 2026. Combined with the Abbott heritage from the 2013 spin-off, the payment record spans decades of consecutive annual increases.

Coverage improved materially as the ex-Humira lineup scales. Q2 2026 revenue rose 10.2% to $16.99 billion with adjusted diluted EPS of $3.65. Operating margin runs at 32.8%, interest coverage sits at 6.94x, and net debt/EBITDA is a comfortable 2.26x. Negative book value shows up in the ratios because of Allergan goodwill and intangibles: an accounting artifact rather than a distress signal.

The bull case rests on Skyrizi and Rinvoq. Skyrizi grew 24.4% to $5.51 billion in Q2, Rinvoq added 24.5% to $2.53 billion, and neuroscience climbed 20.3%. Guidance for 2026 adjusted EPS is $13.87 to $14.07. The risk: continued Humira biosimilar erosion of 35.9% to $756 million, plus integration risk from the $10.9 billion Apogee Therapeutics acquisition that closed September 3, 2026.

Procter & Gamble: 70 Straight Years of Raises

Procter & Gamble (NYSE:PG) yields 2.98% on a quarterly payout of $1.0885 per share. The company just marked its 70th consecutive year of dividend increases and 136th consecutive year of dividend payments, dating to its 1890 incorporation. Few records anywhere are longer.

The safety cushion is deep. Fiscal 2026 free cash flow reached $15.84 billion, up 12.7%, and operating cash flow hit $19.56 billion. Management's fiscal 2027 capital return plan calls for roughly $10 billion in dividends and $5 billion in buybacks. The balance sheet holds $9.94 billion in cash against $54.3 billion of shareholders' equity.

The bull case is durability. Q4 fiscal 2026 core EPS of $1.43 beat consensus for a fifth straight quarter, and Beauty organic sales grew 4%. The caveat: pricing power is constrained. Q4 organic sales were flat, core gross margin contracted 60 basis points, and fiscal 2027 guidance calls for a roughly $1 billion after-tax commodity and transportation headwind, an 8% drag. Growth will be low-single digits, but the dividend keeps compounding (we ranked ten Dividend Kings like P&G by valuation right now in a free report you can grab here).

Bottom Line

These five names cover the income spectrum from Realty Income's monthly high-yield distributions to P&G's 70-year raise streak, and every dollar of yield they generate lands inside a Roth IRA untouched by federal tax. Realty Income solves for cadence and headline yield, J&J and AbbVie deliver healthcare cash flow with visible growth engines, and Coca-Cola and P&G supply the low-beta ballast that keeps a retirement bucket compounding through cycles. Held together in a Roth, the reinvested dividends become the whole point.

Got $1,000? Before You Buy JNJ, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And JNJ wasn't one of them.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>

Contact editorial@247wallst.com for any questions or corrections.